Entera Bio

Entera Bio Debt/Market Cap

The Debt to Market Capitalization Ratio of Entera Bio (ENTX) as of Nov 21, 2026 is 0.90 %. In the previous year, Debt to Market Capitalization Ratio was 0.50 % — a change of 80.15% (higher).

Debt/Market Cap

0.90 %

YoY

80.15%

Last updated:

Debt to Market Capitalization Ratio of Entera Bio is 2025 0.90 % . Debt to Market Capitalization Ratio of Entera Bio was 2024 0.50 % . It decreases by 80.15% higher compared to the previous year.

The Entera Bio Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2017
7.13 USD
Jan 1, 2019
0.55 USD
Jan 1, 2020
0.79 USD
Jan 1, 2021
0.55 USD
Jan 1, 2022
0.17 USD
Jan 1, 2023
0.71 USD
Jan 1, 2024
0.50 USD
Jan 1, 2025
0.90 USD
The Entera Bio Debt/Market Cap history
YEARDebt/Market CapYoY
0.90 %+80.15%
0.50 %-30.26%
0.71 %+328.57%
0.17 %-69.87%
0.55 %-30.09%
0.79 %+44.48%
0.55 %-92.32%
7.13 %-73.55%
26.97 %+82.79%
14.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Debt to Market Capitalization Ratio of Entera Bio is 0.90 % in 2025.

Debt to Market Capitalization Ratio of Entera Bio changed from 0.50 % to 0.90 %, representing a 80.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Entera Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Entera Bio

All Key Metrics — Entera Bio